Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
16/07/2025 09:37
July 16 (Reuters) - Suven Life Sciences Ltd SUVP.NS: RANDOMIZES FIRST PATIENT IN PHASE-2B TRIAL FOR MDD FIRST PATIENT RANDOMIZED IN PHASE-2B CLINICAL TRIAL OF ROPANICANT Source text: ID:nNSEb3B8xF Further company coverage: SUVP.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees